这项研究评估了0.05%异黄酮软膏对小鼠模型中咪喹莫特产生的银屑病样皮肤炎症的潜在积极影响。将32只雄性白化病小鼠分为四组:对照组(每天两次接受局部润肤剂,持续16天),诱导组(接受咪喹莫特乳膏(5%)8天,每天两次,然后是凡士林凝胶(15%),再持续8天),和其他两组,服用咪喹莫特乳膏(5%)8天,然后每天两次服用氯倍他索软膏(0.05%)或异氧西平软膏(0.05%),再服用8天。实验结束时,按伦理标准处死小鼠,和TNF-α的水平,IL-6,IL-17A,测量IL-23和VEGF;检查PASI和Backer评分,除了皮肤组织的组织病理学。每个氯倍他索和异氧苄素组均显示出TNF-α的组织匀浆水平显着降低,IL-6,IL-17A,IL-23和VEGF,除了与诱导组相比IL-10的增量。一些标志物(IL-17A,IL23和VEGF)在氯倍他索和异氧苏氨酸组之间没有显着差异。相比之下,其他标志物(TNF-α,IL6和IL10)在氯倍他索和异氧胺组之间显示出显着差异。Isoxsuprine软膏在治疗咪喹莫特诱导的银屑病样皮肤炎症小鼠模型中显示与氯倍他索软膏相当的功效,可能是由于其抗炎和免疫调节活性的可能作用。
This study assesses the potential positive impact of a 0.05% isoxsuprine ointment on psoriasiform skin inflammation generated by
imiquimod in mouse models. Thirty-two male albino mice were allocated into four groups: the control group (which received topical emollients twice daily for 16 days), the induction group (which received
imiquimod cream (5%) for 8 days, twice daily followed by petrolatum gel (15%) for another 8 days), and the other two groups, which received
imiquimod cream (5%) for 8 days followed by either clobetasol ointment (0.05%) or isoxsuprine ointment (0.05%) twice daily for an additional 8 days. At the end of the experiment, mice were sacrificed by ethical standards, and levels of TNF-α, IL-6, IL-17A, IL-23, and VEGF were measured; PASI and Backer\'s score were examined, in addition to the histopathology of skin tissue. Each clobetasol and isoxsuprine group displayed a significant reduction in tissue homogenate levels of TNF-α, IL-6, IL-17A, IL-23, and VEGF, besides increments in IL-10 compared to the induction group. Some markers (IL-17A, IL23, and VEGF) showed no significant difference between clobetasol and the isoxsuprine group. In contrast, the other markers (TNF-α, IL6, and IL10) showed significant differences between clobetasol and isoxsuprine groups. Isoxsuprine ointment showed comparable efficacy to clobetasol ointment in treating
imiquimod-induced psoriasiform skin inflammation in mice models, probably due to its possible effect of anti-inflammatory and immunomodulatory activities.